Incyte Corporation ( NASDAQ: INCY) Talks About ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer October 19, 2025 1:30 PM EDT
Business Individuals
Pablo Cagnoni – President and Head of Research Study & & Advancement
Patrick Mayes – Vice President of Biotherapeutic Research Study
Ekaterine Asatiani
Steven Stein – Executive VP & & Chief Medical Officer
Teleconference Individuals
Evan Seigerman – BMO Capital Markets Equity Research Study
Michael Schmidt – Guggenheim Securities, LLC, Research Study Department
Salveen Richter – Goldman Sachs Group, Inc., Research Study Department
Reni Benjamin – People JMP Securities, LLC, Research Study Department
Eric Schmidt – Cantor Fitzgerald & & Co., Research Study Department
Marc Frahm – TD Cowen, Research Study Department
Discussion
Pablo Cagnoni
President and Head of Research Study & & Advancement
We’re going to get begun. Thank you, everybody, for joining us here in Berlin, and there are much more of you that are online. Invite to the strong growth upgrade that we’re having at ESMO 2025. We’re really thrilled about 2 programs that we’re going to discuss today. We’re going to concentrate on 2 strong growth programs, our TGF-beta receptor II by PD-1 bispecific and our KRAS G12D inhibitor. Information for both programs existed here at ESMO. Among them existed on Friday other existed previously today.
We will be making positive declarations. And let me stroll you through the program that we have for today. We have 3 members of our group that will stroll you through the biology reasoning for our bispecific. Patrick Mayes, our CSO, will do that. Eka Asatiani, Head of Early Advancement, will discuss the 2 programs of the 2 information sets for TGF-beta and for G12D. And Steven Stein, our Chief Medical Officer, will discuss the future prepare for these 2 programs. We’ll have lots of time for concerns, and we’ll enjoy to deal with as a number of those as you have.
Source: Seeking Alpha.
